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SUMMARY
Erectile dysfunction (ED) is a highly prevalent disease whose aetiology is mostly vasculogenic. It is nowadays considered a marker of
future cardiovascular events reflecting the underlying endothelial dysfunction, the common link with the metabolic syndrome (MetS).
The recent association betweenMetS, endothelial dysfunction and peripheral artery disease, but not with coronary artery disease (CAD),
suggests that the pathophysiologies of CAD and peripheral artery disease may be distinct. Moreover, several recent studies support an
emerging role for an imbalance of angiogenic growth factor levels like Angiopoietin 1 and 2 in cardiovascular disease, considering its
intimate association with chronic low-grade inflammation. We aim to find a correlation between Angiopoietins levels and systemic
and local endothelial function in MetS and ED patients. Forty-five MetS patients with ED were enrolled. ED severity was assessed by
International Index of Erectile Function questionnaire (IIEF5) and penile duplex Doppler ultrasound (PDDU). Endothelial function was
assessed by Peripheral arterial tonometry (PAT), and serum asymmetric dimethylarginine (ADMA), Ang1 and Ang2 levels. Obesity and
hypertension were the most frequent MetS parameters (91.1 and 88.9% respectively). Severe ED was present in 35.6% of patients. Penile
haemodynamic was impaired in 77.5%. Endothelial dysfunction (PAT criteria) was present in 40.9% of patients. Ang2 levels were signifi-
cantly higher in men with abdominal obesity. We observed an inverse correlation between Ang1 and peak systolic velocity, and in
patients with penile arterial dysfunction, Ang1 levels were significantly higher and Ang2/Ang1 ratio significantly lower, than patients
with normal arterial function. Neither ADMA nor PAT parameters were correlated with ED severity evaluated by IIEF5 or PDDU exam.
In conclusion, there is an imbalance of angiopoietins in MetS and ED patients. The absence of correlation with PAT or ADMA levels
suggests that angiopoietins may be early markers of endothelial dysfunction in this population of higher cardiovascular risk.
INTRODUCTION
Erectile dysfunction (ED), the inability to achieve and/or
maintain an erection sufficient to permit satisfactory inter-
course, is a highly prevalent disease whose aetiology is mostly
vasculogenic Brunner et al. (2005), McKinlay (2000). It is associ-
ated with subclinical coronary artery disease (CAD) and is nowa-
days considered a marker of future cardiovascular events B€ohm
et al. (2010), Dong et al. (2011), Montorsi et al. (2003). The
higher prevalence of ED in patients with cardiovascular risk fac-
tors (CVRF) reflects the underlying endothelial dysfunction,
defined as the reduction in nitric oxide (NO) bioavailability.
Metabolic syndrome (MetS) which represents a cluster of sev-
eral CVRF, as abdominal obesity, dyslipidaemia, hypertension
(HTA) and glucose intolerance, it is also associated with an
increased risk of diabetes and cardiovascular diseases, with a
positive correlation with ED Esposito et al. (2005), Grundy
(2007), Tomada et al. (2011). Nevertheless, the CODAM study
demonstrated an unequivocal association between MetS, endo-
thelial dysfunction and peripheral artery disease, but not with
CAD Jacobs et al. (2011). This observation suggests that the
pathophysiologies of CAD and peripheral artery disease may
therefore be distinct.
Several recent studies support an emerging role for an imbal-
ance of angiogenic growth factor levels in disease processes
including tumour growth, diabetes and cardiovascular disease
Augustin et al. (2009), Iribarren et al. (2011), Lim et al. (2005).
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Angiopoietin–Tie system, of which Angiopoietin 1 (Ang1) and
Angiopoietin 2 (Ang2) have been the most studied, is an endo-
thelial cell-specific ligand–receptor axis that regulates vasculo-
genesis and angiogenesis. It is also profoundly involved in the
pathogenesis of inflammation, Ang1 and Ang2 presenting a
counteracting relationship: Ang1 seems to have an anti-inflam-
matory role, whereas Ang2 works opposite by exerting a proin-
flammatory effect Imhof & Aurrand-Lions (2006). In healthy
individuals, serum Ang1 levels are normally high, whereas serum
Ang2 levels are low. In view of the contrasting roles of Ang1 and
Ang2, a deregulation of the balance between Ang1 and Ang2 may
be associated with disease states that cause inflammation and
vascular permeability.
Recently, we demonstrated Ang1 and Ang2 upregulation in
healthy human-aged penile tissue Tomada et al. (2010). Further-
more, Ang1 has been shown to induce successful therapeutic
angiogenesis in animal model. Intracavernous delivery of the
recombinant COMP-Ang1 protein successfully restored the
endogenous NO-cGMP pathway through the regeneration of
healthy and non-leaky cavernous endothelium and inhibition of
reactive oxygen species-mediated cavernous endothelial cell
apoptosis Jin et al. (2011). Moreover, in animal myocardial
infarction and reperfusion models, shifting the Ang2/Ang1 ratio
to favour Ang1 by administration of adenovirus expressing Ang1
could prevent myocardial and endothelial cell apoptosis, and
reduce infarct size. However, shifting the Ang2/Ang1 ratio to
favour Ang2 results in a significant increase in myocardial infarct
size Tuo et al. (2008). It is therefore plausible that angiopoietins
could exert both protective and deleterious effects in the devel-
opment of cardiovascular disease.
In this context, considering the intimate association of chronic
low-grade inflammation with atherosclerosis, Angiopoietin lev-
els and Ang2/Ang1 ratio may be early markers of endothelial
dysfunction, and its assessment may represent a new and accu-
rate test to early detection of cardiovascular risk. Although
abnormal serum angiopoietin levels have been reported in vari-
ous cohorts with concomitant vascular disease, patients with
MetS and ED have not been investigated to date. In addition,
there is no known previous study on the association between
angiopoietins and different markers of endothelial function
systemic and local, resulting in a comprehensive evaluation of
the endothelium in this particular group of patients. Our aim in
this study was to find a correlation between Angiopoietin levels
and systemic and local endothelial function in patients with high
risk of cardiovascular disease, both MetS and ED.
METHODS
Patients
We enrolled 45 consecutive white patients with MetS [National
Cholesterol Education Program – Third Adult Treatment Panel;
Expert Panel on Detection, Evaluation, and Treatment of High
Blood cholesterol in Adults (NCEP-ATPIII) criteria] referred to
our department for ED between August 2010 and January 2012
NCEP Expert Panel (2002). This prospective study protocol was
approved by the Local Ethical Committee of our Hospital and
written informed consent form was obtained from all partici-
pants. Exclusion criteria included recent cardiovascular event
(<6 months), pelvic surgery or trauma, liver and/or renal failure,
chronic and acute inflammatory diseases, tumours and
urogenital abnormalities. A standardized health questionnaire
covering medical history, including sexual history, CVRF and
current medications was obtained. Patients were also asked to
complete the abridged five-item version of the International
Index of Erectile Function (IIEF-5) Rosen et al. (1999). The possi-
ble scores for the IIEF-5 range from 5 to 25, and ED was classi-
fied into five categories based on the scores: severe (5–7),
moderate (8–11), mild to moderate (12–16), mild (17–21) and no
ED (22–25). All patients underwent a standardized physical
examination protocol. Anthropometric evaluation, including
weight, height and waist circumference (WC), was acquired by
the same technician, with the subjects in light clothing and bare-
foot. Body mass index (BMI) was calculated as weight in kilo-
grams divided by square of the height in metres (kg/m2). WC
measurement was obtained using an anthropometric tape (to
the nearest 0.1 cm) at the end of normal expiration at the level
of the midpoint between the lower end of the 12th rib and upper
end of iliac crest.
Systolic and diastolic blood pressures were measured in the
right arm using an automatic manometer (DINAMAP Procare
300: GE, Buckinghamshire, UK) in the sitting position after a 10-
min rest period. HTA was defined as systolic blood pressure
130 mmHg and/or diastolic blood pressure 85 mmHg. All
patients were studied between 8 and 10 AM after a 12-h overnight
fast. Venous blood was sampled for measurements of plasma
glucose, total and high-density lipoprotein cholesterol (HDL),
triglycerides (Trig), by routine laboratory methods. Total testos-
terone (TT) levels were determined by electrochemilumines-
cence in an immunoassay analyser (Cobas; Roche Diagnosis
GmbH, Mannheim, Germany) with a normal range 9.7–
27.8 nmoL/L. Free testosterone (FT) levels were calculated
according to Vermeulen formula as previously described Verme-
ulen et al. (1999).
Hypogonadism was defined as TT below 8 nmoL/L or FT
under the lower limit of range when the serum TT level was
between 8 and 12 nmoL/L, according to the International
Society of Andrology, International Society for the Study of Aging
Male, European Association of Urology, European Academy of
Andrology and American Society of Andrology recommenda-
tions Wang et al. (2009).
Penile duplex Doppler ultrasound exam
All patients underwent PDDU examination using a standard
protocol, as recommended in the ‘Standard Practice in Sexual
Medicine’, produced by the International Society for Sexual Med-
icine Standards Committee, as previously described Tomada
et al. (2011). Patients were not under acute or chronic use of
phosphodiesterase type 5 inhibitors for at least 30 days until
PDDU assessment. Briefly, penile Doppler measurements of
spectral waveforms were performed including peak systolic
velocity (PSV), end diastolic velocity (EDV) and resistive index
(RI). Measurements were made at 5, 10 and 20 min, and the
mean of the latest values were recorded. Values of PSV higher
than 35 cm/sec, EDV lower than 5 cm/sec and RI >1 were con-
sidered normal response. Diagnostic criteria for an abnormal
response included arterial insufficiency for PSV <35 cm/sec or
PSV asymmetry >10 cm/sec, and cavernous venous-occlusive
disease for PSV ≥35 cm/sec and EDV ≥5 cm/sec. The degree of
erectile response was estimated according to a graded scale: 0
(no response), 1 (minimal tumescence and no rigidity), 2
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(moderate tumescence and no rigidity), 3 (full tumescence and
moderate rigidity) and 4 (full rigidity).
Peripheral arterial tonometry evaluation
The PAT evaluation was performed with patient in a supine
position in a dimly lit, noise and temperature-controlled room
Patvardhan et al. (2010), Hamburg et al. (2008). All vasoactive
medications were discontinued 24 h prior to testing. Patients
were instructed to have a light meal on the morning of the exam
and to refrain from exercise, smoking and caffeine consumption
on that day. Peripheral wave amplitude was assessed before and
during reactive hyperaemia (RH) by PAT (Endo-PAT 2000; Itamar
Medical Ltd., Caesarea, Israel) as previously described Aversa
et al. (2011). Following a 10-min acclimatization period, 5-min
RH-PAT baseline signals were recorded using plethysmographic
finger cuffs, placed on the index finger of both hands. The blood
pressure cuff was then inflated rapidly to 200 mmHg and
remained at that level for 5 min before being quickly released,
and then PAT tracing was recorded for another 5 min. RT-PAT
index was calculated as the ratio of the average amplitude of the
PAT signal over a 1-min time interval starting 1 min after cuff
deflation divided by the average amplitude of the PAT signal of a
3.5-min time period before cuff inflation. The index was calcu-
lated through a computer algorithm automatically normalizing
for baseline signal and indexed to the contralateral arm. Endo-
thelial dysfunction was defined using a 1.67 RH-PAT cut-off
Ohno et al. (2010). Arterial stiffness was also measured through
the augmentation index (AI) calculated as the ratio between the
amplitude difference of the two systolic peaks and the amplitude
of the first peak. The larger the value of AI, the stiffer the arterial
system, negative values being possible when first peak is higher
than second.
Angiopoietins and asymmetric dimethylarginine quantification
Ang1 and Ang2 were quantified by ELISA (DANG10 and
DANG20 Immunoassay; R&D Systems, Abingdon, UK respec-
tively) in 50 lL of human serum according to the manufac-
turer’s instructions. Quantifications were performed at 450
and 550 nm using a plate reader (Multiskan Ascent; Thermo
Electron Corporation, Waltham, MA, USA). ADMA was also
quantified by ELISA (EA201/96 Immunoassay; DLD Diagnos-
tika GMBH, Hamburg, Germany) in 20 lL of human serum
according to the manufacturer’s instructions. Quantifications
were performed at 450 and 600 nm using a plate reader
(Multiskan Ascent; Thermo Electron Corporation). These
ELISA assays were performed by an investigator blinded to
the sources of the samples.
Statistical analysis
All descriptive data are expressed as mean value  standard
deviation for the continuous variables and as percentage for the
categorical variables. Pearson correlation was performed to eval-
uate the association between continuous variables including
between the different markers of endothelial function and mark-
ers of endothelial function and clinical variables, MetS criteria,
severity of ED and PDDU haemodynamic findings. Some
specific correlations are presented with scatter plot graphs with
a line of best fit. Statistical analysis was performed using SPSS
version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Statisti-
cal significance was considered at p-level <0.05.
RESULTS
The characteristics of the study population are described in
Table 1. Mean age, BMI and WC were 55.4  7.8 years, 31.6 
5 kg/m2 and 112  11.4 cm respectively. Insulin resistance, HTA,
hypercholesterolaemia, hypertriglyceridaemia and HDL below
1.03 mmol/L were identified in 71.1, 88.9, 75.6, 75.6 and 64.4% of
patients respectively. Three, four and five components of MetS
were present in 33.3, 42.2 and 24.4 of the patients respectively.
Hypogonadism was present in 44.4% of the patients, being
severe (TT below 8 nmoL/L) in 13.3%. A history of tobacco use
was present in 71.1% of the patients. Relevant current medical
treatment included angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, beta blockers, diuretic agents, sta-
tins, acetylsalicylic acid and antidepressives in 35.6, 33.3, 28.9,
44.4, 55.6, 48.9 and 6.7% of the patients respectively. Obesity
defined by BMI ≥30.0 kg/m2 was present in 97.8%.
The mean IIEF-5 score was 10.4  5.2. ED severity as assessed
by this questionnaire was as follows: no ED-6.7%, mild ED-4.4%,
mild to moderate ED-24.4%, moderate ED-28.9%, and severe
ED-35.6%.
The PDDU was normal in 22.5%, arterial insufficiency was
present in 55% of the cases and veno-occlusive dysfunction in
22.5%.
Table 1 Characteristics of the study population. Data are expressed as
mean  standard deviation when normally distributed and as percentages
when categorical
Age (years) 55.4  7.8
Weight (kg) 91.4  17.3
Waist circumference (cm) 112.0  11.4
BMI (Kg/m2) 31.6  5.0
TT (nmol/L) 13.22  4.62
SHBG (nmol/L) 34.8  19.1
cFT (pmol/L) 260  94
Bioavailable testosterone (nmol/L) 6.42  2.26
SBP (mmHg) 140.6  17.5
DBP (mmHg) 82.7  9.1
Glucose (mmol/L) 6.93  3.12
Cholesterol (mmol/L) 4.70  0.85
Triglyceride (mmol/L) 1.99  0.87
HDL cholesterol (mmol/L) 1.07  0.21
IIEF-5 10.4  5.2
No ED (%) 6.7
Mild ED (%) 4.4
Mild to moderate ED (%) 24.4
Moderate ED (%) 28.9
Severe ED (%) 35.6
Metabolic syndrome components (NCEP-ATP III) (%)
HTA (>130/85 mmHg) or treatment 88.9
Hypertriglyceridaemia (>1.7 mmol/L) or treatment 75.6
Insulin resistance (fasting plasma glucose ≥6.1 mmol/L) 71.1
Low HDL (<1.03 mmol/L) or treatment 64.4
Waist circumference >102 cm 91.1
Smokers (%) 71.1
Current medical treatment (%)
ACE inhibitors 35.6
AR blockers 33.3
Beta blockers 28.9
Diuretic agents 44.4
Statins 55.6
Acetylsalicylic acid 48.9
Antidepressives 6.7
Hypogonadism (%) 44.4
BMI: body mass index, TT: total testosterone, SHBG: Sex Hormone–Binding
Globulin, cFT: calculated free testosterone, ED: erectile dysfunction, IIEF-5:
abridged 5-item version of the International Index of Erectile Function, HTA:
hypertension, HDL: high-density lipoprotein, ACE: angiotensin-converting
enzyme, AR: angiotensin receptor.
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Endothelial dysfunction defined by PAT was present in 40.9%
of the patients. Mean RH-PAT and AI were 1.8  0.4 and
8.6  21.1 respectively.
Mean levels of ADMA, Ang1 and Ang2 were 0.56  0.24 lmol/
L, 11.10  1.95 ng/mL and 3.0  0.56 ng/mL respectively.
Clinical correlations
ED severity, evaluated by IIEF-5 score, increased with age
(r = 0.386; p = 0.009). Bioavailable testosterone was associated
with BMI (r = 0.348; p = 0.032), unlike TT (r = 0.222;
p = 0.153) or calculated FT (r = 0.288; p = 0.079).
Correlations between markers of endothelial function and
clinical variables
Among all parameters of EndoPAT only AI correlated inversely
with BMI (r = 0.400; p = 0.007) and positively with systolic
arterial blood pressure values (r = 0.486; p = 0.001). There were
no correlations between ADMA and clinical variables (data not
shown). Ang1 presented an inverse correlation with ageing
(r = 0.368; p = 0.020). Ang2 presented a positive correlation
with BMI (r = 0.422; p = 0.007) and an inverse correlation with
TT, bioavailable testosterone and calculated FT (r = 0.428,
p = 0.006; r = 0.398, p = 0.018; and r = 0.415, p = 0.013;
respectively).
Correlations between markers of endothelial function and
MetS criteria
We failed to observe a correlation between EndoPAT parame-
ters, ADMA or Angiopoietins with increasing criteria for MetS.
There was also no correlation of any of these markers with any
single parameter of MetS, with the exception of Ang2 levels
being significantly higher in patients with WC >102 cm
(p = 0.047) and a trend to be elevated in patients with HDL levels
<40 mg/dL (p = 0.057) (Table 2).
Correlations between markers of endothelial function and
severity of ED evaluated by IIEF5
We could not demonstrate a correlation between Ang1, Ang2,
Ang2/Ang1 ratio, ADMA and EndoPAT parameters RH-PAT and
AI with the severity of ED as evaluated by IIEF5 questionnaire
(r = 0.019, p = 0.907; r = 0.277, p = 0.084; r = 0.156,
p = 0.336; r = 0.221, p = 0.171; r = 0.038, p = 0.805;
r = 0.156, p = 0.313; respectively).
Correlations between markers of endothelial function and
PDDU haemodynamic findings
We observed an inverse correlation between Ang1 and PDDU
haemodynamic parameters PSV (r = 0.451, p = 0.005) (Fig. 1)
and EDV (r = 0.524, p = 0.003), whereas Ang2/Ang1 ratio pre-
sented a direct correlation (r = 0.350, p = 0.034; r = 0.465,
p = 0.010 respectively). There were no correlations between Ang2
(r = 0.002, p = 0.990; r = 0.097, p = 0.610 respectively),
ADMA (r = 0.116, p = 0.494; r = 0.294, p = 0.114 respectively), RH-
PAT (r = 0.155, p = 0.347; r = 0.34, p = 0.855; respectively) and AI
(r = 0.138, p = 0.401; r = 0.029, p = 0.877; respectively) with those
same parameters.
When we considered patients with arterial dysfunction, Ang1
levels were significantly higher (p = 0.015) and Ang2/Ang1 ratio
significantly lower (p = 0.048), than patients with normal arterial
function in PDDU examination.
Correlations between the different markers of endothelial
function
The ADMA presented an inverse correlation with Ang1
(r = 0.452, p = 0.003) and a positive correlation with Ang2/
Ang1 ratio (r = 0.429, p = 0.006). There were no correlations
Table 2 Results of analysis of the relationship between EndoPAT parameters, ADMA and Angiopoietins with MetS parameters. There was no correlation of
any of these markers with any single parameter of MetS, with the exception of Ang2 levels being significantly higher in patients with WC >102 cm
(p = 0.047)
Metabolic syndrome
components
(NCEP-ATP III)
Waist circumference
>102 cm
HTA
(>130/85 mmHg)
or treatment
Insulin resistance
(fasting plasma
glucose ≥6.1 mmol/L)
Hypertriglyceridaemia
(>1.7 mmol/L) or treatment
Low HDL
(<1.03 mmol/L) or treatment
RH-PAT 0.790 0.862 0.371 0.118 0.646
AI 0.554 0.691 0.587 0.878 0.844
ADMA 0.795 0.228 0.644 0.488 0.665
Ang1 0.788 0.261 0.692 0.112 0.274
Ang2 0.047 0.954 0.587 0.467 0.057
Ang2/Ang1 0.176 0.472 0.855 0.229 0.624
HTA: hypertension, HDL: high-density lipoprotein, RH-PAT: reactive hyperaemia by peripheral arterial tonometry, AI: augmentation index, ADMA: Asymmetric dime-
thylarginine, Ang1: Angiopoietin 1, Ang2: Angiopoietin 2.
Bold indicates statistically significant value.
Figure 1 Correlation between Ang1 serum levels and peak systolic velocity
(r = 0.45, p = 0.005).
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between EndoPAT parameters and angiopoietins or ADMA
serum levels (data not shown).
DISCUSSION
The MetS is a cluster of metabolic risk factors, responsible for
a greater risk of developing cardiovascular disease and diabetes.
ED often coexists with CVRF and has been recently recognized
as a predictor of future cardiovascular events B€ohm et al. (2010).
Moreover, the prevalence of ED is increased in men with MetS
compared with the general population Lee et al. (2012). Several
evidences have revealed the relationship existing between the
earliest stages of atherosclerosis, such as the impairment of
endothelial function, and MetS components (Fig. 2). The
perivascular smooth muscle relaxation dependence of the NO
produced by endothelial NO synthase (eNOS) is regulated by
insulin. Insulin-resistant conditions such as diabetes, MetS and
obesity significantly contribute to endothelial dysfunction by
disrupting the NO cascade, resulting first in a loss of arterial
capacity to dilate and finally in increased atherosclerosis, with
subsequent vascular compromise Ryan & Gajraj (2012), Vaudo
et al. (2007). This endothelial dysfunction is believed to be the
common key mechanism in the pathogenesis of ED and MetS.
Understanding this pathophysiological pathway has particular
clinical relevance in terms of recognizing early micro- and mac-
rovascular dysfunction manifesting as ED.
We recently showed that MetS in ED patients is associated
with deterioration in the haemodynamic parameters of the
cavernosal arteries, particularly with a diminished PSV, as the
number of MetS criteria increased Tomada et al. (2011). More-
over, increased fibrinogen and resting heart rate as well as
impaired arterial elasticity were more evident among subjects
with both conditions, highlighting the higher cardiovascular risk
for MetS patients presenting with ED Pohjant€ahti-Maaroos et al.
(2011). Thus, there is an opportunity for the development of new
clinical methods/markers for subclinical atherosclerosis, funda-
mental for public health purposes.
Endothelium evaluation may comprise a multitude of meth-
ods. Local response of cavernous arteries to a pharmacologic
vasodilator stimuli as evaluated by PDDU is an important tool
for the diagnosis and classification of patients with vasculogenic
ED, especially of arteriogenic origin, which reliability in this con-
text has been repeatedly demonstrated Kendirci et al. (2007), La
Vignera et al. (2011), Tomada et al. (2011). More recently, physi-
ological measurements as EndoPAT or systemic methods with
serum markers as ADMA emerged as promising new
alternatives.
The EndoPAT device uses a finger probe to assess digital vol-
ume changes accompanying pulse waves after inducing reactive
hyperaemia with a blood pressure cuff on the upper arm.
RH-PAT has been extensively correlated with early and clinically
relevant CAD. In addition, it is similar to flow-mediated dilation
in representing a true physiological reflection of peripheral
endothelial function Tamler & Bar-Chama (2008). Recently, its
application in men with ED was tested, but an increased arterial
stiffness rather than an impaired reactive hyperaemia demon-
strated by RH-PAT was found in patients with vascular ED inde-
pendently of CVRF presence Aversa et al. (2011).
In our study, a RH-PAT less than 1.67 was observed only in
41% of patients, which means that the majority did not present
with endothelial dysfunction by this method. We could not
demonstrate a correlation between EndoPAT parameters neither
with increasing severity of ED evaluated by IIEF5 questionnaire
or PDDU, nor with increasing MetS criteria. Taken together, this
may represent a state of vascular impairment that precedes the
classical detection of endothelial dysfunction by RH-PAT. More
information regarding the variability in the PAT hyperaemic
response with disease status, and a higher threshold for identify-
ing vascular ED, may be necessary.
Asmentioned above, theNOpathway is of critical importance for
the physiological regulation of penile erectile function and its pro-
duction can be affected by endogenous NOS inhibitors like ADMA.
In various pathological states, such as hypercholesterolaemia,
hyperglycaemia, hyperhomocysteinaemia, HTA and CAD, plasma
levels of ADMAmay be increased and lead to inhibition of NO syn-
thesis and endothelial dysfunction Elesber et al. (2006), Wierzbicki
et al. (2006). Thus, ADMA could be used as a biochemical indicator
of endothelial dysfunction, as it seems to be responsible for the
pathophysiological link between this condition and ED Wierzbicki
et al. (2006). Nevertheless, there are reports of absence of relation-
ship between ADMA and the development of the age-related
impairment of endothelium-dependent vasodilations Gates et al.
(2007). Recently, Ioakeimidis et al. (2011) showed that in patients
with vasculogenic ED, ADMA levels were significantly higher in
subjects with arterial insufficiency than inmenwith venous leakage
alone, while there was also an independent inverse association
between ADMA level and PSV. However, in our sample, there was
no correlation of ADMA levels with arteriogenic ED, and, similar to
Wierzbicki et al. (2006), neither withmarkers of ED severity. Inhibi-
tion of ADMA synthesis or intensification of metabolism of this
compound might indirectly lower ADMA. Several medications like
angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, acetylsalicylic acid and also some hypolipaemic, hypogly-
caemic and beta-adrenoreceptor blocking drugs decrease ADMA
levels Trocha et al. (2010). Considering the higher percentage of
consumption of these substances in our patients, its influence
cannot be excluded.
The vascular endothelium is considered a systemically
disseminated organ that is maintained in a quiescent state in
healthy individuals. The loss of quiescence is associated with
severe pathology. Although cardiovascular events such as
myocardial infarction and stroke are often sudden conditions,
long-term subclinical structural and functional changes in the
Figure 2 Mechanisms responsible for the increased risk of cardiovascular
disease in patients with metabolic syndrome.
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vascular wall precede overt atherosclerotic disease. This vascular
remodelling is at least in part mediated by vascular growth
factors that may be a link between CVRF and atherosclerosis
Kaess et al. (2012). Angiopoietins, a distinct family of angiogenic
proteins, have recently been shown to play fundamental physio-
logical roles in the maintenance of vascular integrity Augustin
et al. (2009). Ang1 and Ang2 play divergent roles in mediating
cell survival, vascular quiescence and inflammation (Fig. 3).
Indeed, Ang1 has antiapoptotic, antipermeability and anti-
inflammatory properties, whereas Ang2 seems to have opposite
effects. In healthy individuals, serum Ang1 levels are normally
high, contrasting with low serum levels of Ang2. Accordingly, a
deregulation of the balance between Ang1 and Ang2 may be
associated with disease states that cause inflammation and vas-
cular permeability, functioning like true biomarkers of cardio-
vascular disease Augustin et al. (2009), Imhof & Aurrand-Lions
(2006), Iribarren et al. (2011). Despite the promising value of
new endothelial dysfunction biomarkers such as circulating
endothelial progenitor cells, as well as, endothelial microparti-
cles secreted after endothelial cell activation, its detection in
blood is still laborious and technically difficult, particularly
considering that the origin of the EPCs has not yet been fully
clarified La Vignera et al. (2011). Ang–Tie receptor–ligand system
emerges then as a critical regulator of vascular function. In this
setting, circulating levels of Ang1 and Ang2 may provide valuable
information regarding the status of endothelial dysfunction,
which is supported by our findings of angiopoietin levels signifi-
cant correlation with ADMA. Notwithstanding the abnormal
serum angiopoietin concentrations found in the spectrum of
vascular diseases, its status in a particular sample of patients
with both MetS and ED have not been investigated to date.
Adipose tissue is a highly metabolic active and well-vascular-
ized organ, dependent of the presence of angiogenic factors for
its growth and maintenance. In this study, a positive correlation
between BMI and Ang2 levels was found, corroborating the
higher circulating levels of Ang2 observed in overweight and
obese compared with lean individuals Silha et al. (2005). Owing
to BMI limitations on predicting total adiposity mass and its
distribution, and considering the relation of abdominal obesity
with insulin resistance risk, WC gained wide acceptance as a
component of MetS. A direct and significant relation between
Ang2 levels and WC was also observed, highlighting the link with
visceral adipose tissue. This make sense, attending that expan-
sion of this tissue may not be as well vascularized. In this
context, the following hypoxia, a powerful inducer of Ang2
exocytosis from Weibel-Palade Bodies, may justify the higher
serum levels of Ang2 Gealekman et al. (2011).
Adipose tissue constantly experiences expansion and regres-
sion throughout adult life. This plasticity requires continuous
remodelling of the vasculature that controls energy expenditure,
metabolic exchange, transport of adipokines, adipocyte hyper-
trophy and hyperplasia, or even hormones like testosterone and
estradiol Xue et al. (2008). Obesity was present in 98% of our
patients and was significantly associated with reduced levels of
bioavailable testosterone. This may explain the inverse correla-
tion, reported here for the first time, between Ang2 levels and
testosterone measurements in patients with MetS.
We previously demonstrated that HTA is the most important
component of MetS impacting penile peak systolic velocities
Tomada et al. (2011). HTA in the microcirculation is associated
with vessel rarefaction. However, it is not clear whether this is
caused by destruction of the microvessels because of the
increased blood pressure, or caused by impaired angiogenesis,
as abnormalities in indices of angiogenesis, such increased
plasma Ang1 are present in hypertensive patients Nadar et al.
(2005). Although a correlation of Ang1 with HTA could not be
found in our sample, we observed an inverse correlation
between Ang1 levels and PSV, and that in patients with arterio-
genic ED there were a significant increase in Ang1 levels. Angio-
poietins are regulated by a number of factors, including hypoxia
and inflammation. It is likely that in MetS, these angiogenic fac-
tors are increased as a compensatory mechanism. In particular
may be a role for Ang1 as it is considered an endothelial survival
factor and vasculoprotective agent. High levels of Ang1 were
protective against graft coronary arteriopathy in a preclinical
model and, in addition, Ang1 also increases mobilization of
Figure 3 Angiopoietin signalling in quiescent endothelial cells covered by pericytes that constitutively express and secrete Ang1. Ang1 induces Tie2 activa-
tion at endothelial cell–cell junctions, thus promoting EC survival and vessel stabilization. Ang2, which is released from Weibel-Palade bodies upon inflam-
matory stimuli, binds to Tie-2 and behaves as a competitive antagonist by blocking further binding of Ang1.
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endothelial progenitor cells Aicher et al. (2005), Nyk€anen et al.
(2003). Consistent with this reparative potential of Ang1, our
results demonstrated that increased Ang1 may be responsible
for a compensatory attempt for vessel stabilization before
cardiovascular events take place.
CONCLUSIONS
Our observations that Ang1 and Ang2 are deregulated in
patients with ED and MetS support the hypothesis that they may
be involved in the pathogenesis of this syndrome. And more
importantly, our results reinforce the role of ED as amore reliable
predictor of cardiovascular disease considering that in patients
with MetS, ED represents a marker of subclinical atherosclerosis
demonstrated by Angiopoietins correlation with local endothelial
dysfunction and not with systemic markers. However, the cross-
sectional design of this study prevents any definitive causal infer-
ences. In addition, we realize that it is a small sample and thus
additional research is warranted to determine whether the
observed associations are clinically meaningful.
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